Impact of Conventional Cardiovascular Risk Factors on Left Internal Mammary Artery Graft Disease

Hui-Juan Zuo 1*, Nan Nan 2, Hong-Xia Yang 2, Jin-Wen Wang 1 and Xian-Tao Song 2*

1 Department of Community Health Research, Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Diseases, Capital Medical University, Beijing, China, 2 Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Background: The development of atherosclerosis was considered as the common cause of the stenosis of coronary artery grafts. Left internal mammary artery (LIMA) was the best artery graft for further effectiveness of coronary artery bypass grafting (CABG). We sought to assess the impact of known conventional cardiovascular risk factors (RFs) on LIMA graft stenosis.

Methods: A retrospective study including 618 participants, who had recurrence of chest pain after CABG, aged ≥18 years, hospitalized for coronary angiography in Beijing Anzhen hospital between 2010 and 2017 was performed. All the participants were confirmed to have LIMA graft. Multivariate analysis was conducted to determine the relationship between conventional RFs and LIMA graft stenosis.

Results: Of the study, 220 (35.6%) participants continued to smoke, 504 (81.6%) were overweight or obese, and 411 (66.5%) and 242 (39.2%) reported concomitant hypertension and diabetes, respectively. LIMA graft stenosis occurred in 161 participants (26.1%). Postoperative smoking, a CABG duration of ≥10 years and hyperglycemia without diabetes had an increased risk of LIMA graft stenosis, the odds ratio (OR) was 1.86 [95% confidence interval (CI): 1.26–2.78], 2.24 (95%CI:1.33–3.478), and 2.44(95% CI:1.39–4.32), respectively. Statin use (OR, 0.28; 95% CI: 0.25–0.5) and low-density lipoprotein cholesterol (LDL-C) < 1.8 mmol/L (OR, 0.27; 95% CI: 0.14–0.53) had a significantly decreased risk of LIMA graft stenosis. While, only 15.4% (95/618) achieved the target LDL-C level.

Conclusions: Postoperative smoking and hyperglycemia without diabetes had an increased risk of LIMA graft stenosis. Statin use and LDL-C < 1.8 mmol/L decreased the risk.

Keywords: coronary heart disease, coronary artery bypass grafting, left internal mammary artery, atherosclerosis, risk factor

INTRODUCTION

Coronary artery bypass graft (CABG) surgery is the most complete and durable treatment of left main coronary artery and three-vessel coronary severe stenosis or occlusion disease and has been an established therapy for nearly 50 years. Following CABG, effects should be done to reduce the recurrence of cardiovascular event. Studies have shown that the recurrence rate of angina is 17% in...
1 year after CABG and 63% in 10 years after CABG (1), which was associated with native coronary artery disease progression and the development of graft atherosclerosis, and the stenosis of grafts was considered as the most common cause (2).

The grafts were saphenous vein (SV), left internal mammary artery (LIMA), right internal mammary artery (RIMA) and radial artery (RA). Using graft from LIMA to the left anterior descending artery (LAD) improves the effectiveness of CABG with high long-term patency rate (3). The great SV as a second conduit are commonly used for other target vessels of multi-vessel disease, however, they are associated high failure rate; the stenosis rate was more than 20% in 1 year, 40% in 2 years and 60% in 10 years after CABG (4). RA seems to be better graft than SV because prognosis improvement in increasing the long-term survival and decreasing the incidence of cardiovascular events were found in more and more studies (5–7). So, full arterial grafting for further effectiveness of CABG may be the direction (8, 9). Even though RA graft are strongly suggested in CABG surgery as the second graft (5–9), it appears to be underutilized in China with the percentage <1%. Hence, LIMA graft stenosis will be highlighted in this study.

The patency rate of grafts rapidly increases within the first year after CABG and then slowly, which was attributed to anastomotic site stenosis between 1 month and 1 year and atherosclerosis development of the bypass graft 1 year later (10). Dyslipidemia, hypertension, diabetes mellitus, obesity and smoking were considered as conventional risk factors (RFs) for atherosclerosis, which largely contribute to cardiovascular disease (CVD), approximately 70% of native coronary artery case and deaths were attributed to them (11). Are those conventional RFs associated with the development of atherosclerosis in artery grafts? Conflicting evidence was reported in previous studies (12–17). Therefore, we performed this study, enrolled patients who had recurrence of chest pain after performing CABG surgery at least 1 year, analyzed the impact of conventional cardiovascular RFs on LIMA graft stenosis.

**METHODS**

**Participants**

This study was based on a retrospective, single-center analysis of patients who had recurrence of chest pain after CABG and had subsequent coronary angiographic findings in the Department of Cardiology of Beijing Anzhen Hospital from January 2010 to December 2017. All the participants were enrolled through the hospital's electronic record system. The inclusion criteria were an age of ≥ 18 years; recurrence of chest pain after CABG; completed electronic medical records and coronary angiographic findings; underwent LIMA-LAD graft. The exclusion criteria were CABG within 1 year before the start of the study; second CABG; renal insufficiency requiring dialysis treatment; and/or cancer.

Abbreviations: RFs, risk factors; LIMA, left internal mammary artery; CVD, cardiovascular disease; CABG, coronary artery bypass grafting; SV, The grafts were saphenous vein; RIMA, right internal mammary artery; RA, radial artery; LAD, left anterior descending artery; OR, odds ratio; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; ARB, angiotensin receptor blockers; ACEI, angiotensin-converting enzyme inhibitors; BMI, body mass index.

**Data Collection**

Data regarding the patients’ demographics, conventional RFs for CVD, coronary angiographic findings and medication intake were collected from the hospital records by trained abstractors, using physician notes, laboratory reports, patient histories, and discharge summaries. A structured questionnaire was developed. Demographic information consisted of gender, age; conventional RFs included overweight/obese, medical history of hypertension and diabetes, LDL-C level and smoking details. Basic medication therapy for secondary prevention to cardiovascular events included the usage of aspirin, β-blocker, angiotensin receptor blockers (ARB)/angiotensin-converting enzyme inhibitors (ACEI) and statins (dosage and type of those drugs were not obtained in the study). Height, weight, and blood pressure were measured in ward and recorded. The fasting plasma glucose (FPG) and LDL-C concentrations were examined while the patients were hospitalized. Coronary angiographic findings was reviewed, occlusion or stenosis of the native coronary arteries (including the left main, left anterior descending, circumflex, and right coronary arteries) and artery grafts were recorded. Number and stenosis of SV graft was not collected in this study.

**Measurements and Diagnostic Criteria**

Chest pain was identified based on induction factor, position pain, feature of pain, pain duration, radiating pain and remission. We defined severe stenosis for native coronary artery as stenosis of ≥50% for left main, ≥70% for left anterior descending, circumflex, and right coronary arteries; defined artery graft disease as stenosis of ≥ 50%, and at least 1 stenosis was measure in LIMA based on angiography. Uncontrolled blood pressure was defined as SBP of ≥140 mmHg and/or DBP of ≥90 mmHg, and controlled blood pressure was defined as SBP of <140 mmHg and DBP of <90 mmHg. The body mass index (BMI) was calculated as body mass in kilograms divided by height in meters squared. Normal weight was defined as a BMI of <24.0 kg/m², an overweight status was defined as a BMI of 24.0 to 27.9 kg/m², and obese was defined as a BMI of ≥28.0 kg/m². Ideal target of LDL-C was defined as an LDL-C concentration of <1.8 mmol/L (70 mg/dl). Ideal target of blood glucose was defined as an FPG of <7 mmol/L (126 mg/dl). The presence of hypertension or diabetes was defined by a previous diagnosis of hypertension or diabetes in the document of diagnosis on admission or summary of history. Nonsmokers were defined as patients who had never smoked, ever-smokers who stopped smoking at least 6 months, and current smokers were defined as those who were smoking every day or some days after CABG or stopped smoking <6 months at the time of interview.

**Statistical Analysis**

The statistical analysis was performed with SPSS software for Windows, version 18.0 (SPSS, Inc., Chicago, IL, USA). Normally distributed continuous variables are presented as means ± standard deviations. A student's t-test was used to compare two independent samples. Categorical variables are expressed as proportions. The chi-square test was used to compare the differences in proportions between different groups. Multiple
backward stepwise logistic regressions were performed to identify the association between risk factors and artery graft disease. All significant variables based on the chi-square test were entered into a multivariate model. All reported $P$ values were two-tailed, and $P < 0.05$ were considered statistically significant.

## RESULTS

### General Information

A total of 618 participants (male: $n = 500$, female: $n = 118$), 13 (2.1%) together with RIMA graft and 4 (0.65%) together with RA graft. The age ranged from 37 to 75 years (mean, 63.6 ± 8.8 years). Mean interval after CABG was 6.4 ± 2.1 years (range from 1 to 18 years), and 83.8% of them had undergone CABG <10 years prior to the study. The prevalence of conventional RFs was postoperative smoking 220 (35.6%), overweight or obese 504 (81.6%), hypertension 411 (66.5%), diabetes 242 (39.2%), and 15.4% (95 of 618) achieved LDL-C target level of <1.8 mmol/L. Recurrent angina was the most common presentation (93.4%, 577/618). According to the cut-off point of coronary artery stenosis, 298 (48.2%) patients had a left main disease, 473 (76.5%), 383 (62.0%), and 269 (43.5%) had a severe stenosis in LAD, circumflex coronary artery, and right coronary artery, respectively. LIMA graft stenosis occurred in 161 participants (26.1%). Main characteristics of the overall sample are presented in Table 1.

### Mean Level and Optimal Control for Conventional RFs According to LIMA Graft Stenosis

Mean LDL-C level was 2.94 mmol/L among patients with LIMA graft stenosis, which was higher than that in those without LIMA graft stenosis (2.69 mmol/L, $P=0.033$). For mean level of SBP, DBP, FPG and BMI, no correlation with LIMA graft stenosis was observed (all $P >0.05$). Higher proportion of patients with LDL-C <1.8 mmol/L was observed in patients without LIMA graft stenosis than that in those with LIMA graft stenosis (18.2 vs. 7.5%, $P = 0.001$). There were significant differences in the proportion of FPG <7.0 mmol/L and smoking cessation across LIMA graft stenosis groups ($P<0.05$). There were no significant differences of the proportion of BMI <24 kg/m² and BP <140/90 mmHg between the two groups (Table 2).

### Correlation of Conventional RFs With LIMA Graft Stenosis

Of 618 patients, 161 (26.1%) developed LIMA graft stenosis, which did not vary by sex, age group, BP group, BMI group, and use of aspirin, ACEI/ARB and β-blocker (all $P > 0.05$). It was more frequent among patients without history of diabetes who had an FPG≥7.0 mmol/L, with postoperative smoking, or with a duration of CABG≥10 years (all $P < 0.05$); lower prevalence was observed among patients with LDL-C<1.8 mmol/L and taking statin ($P = 0.001$). Multivariate logistic regression analysis was
TABLE 3 | Prevalence of LIMA graft stenosis and the relationship between LIMA graft stenosis and conventional RFs.

| Characteristics                  | Number | Prevalence of LIMA graft stenosis | Multivariate analysis |
|----------------------------------|--------|----------------------------------|-----------------------|
|                                  |        | n (%)                            | P value               | OR (95% CI) | P value       |
| **Gender**                       |        |                                  |                       |             |               |
| Male                             | 500    | 127 (25.4)                       | 0.447                 |             |               |
| Female                           | 118    | 34 (28.8)                        |                       |             |               |
| **Age group (y)**                |        |                                  |                       |             |               |
| <65                              | 313    | 77 (24.6)                        | 0.405                 |             |               |
| ≥65                              | 305    | 84 (27.6)                        |                       |             |               |
| **Duration of CABG (y)**         |        |                                  |                       |             |               |
| <5                               | 236    | 55 (23.3)                        | 0.021                 | 1           |               |
| 5–9                              | 266    | 64 (24.1)                        | 1.11 (0.72–1.72)      | 0.641       |               |
| ≥10                              | 116    | 42 (36.2)                        | 2.24 (1.33–3.78)      | 0.003       |               |
| **Blood pressure (mmHg)**        |        |                                  |                       | 0.196       |               |
| HP− BP < 140/90                  | 185    | 48 (25.9)                        |                       |             |               |
| BP ≥140/90                       | 22     | 10 (45.5)                        |                       |             |               |
| HP+ BP < 140/90                  | 227    | 55 (24.2)                        |                       |             |               |
| BP ≥140/90                       | 136    | 48 (26.1)                        |                       |             |               |
| **Blood glucose (mmol/L)**       |        |                                  |                       | 0.006       |               |
| DM− FPG < 7.0                    | 303    | 70 (23.1)                        |                       |             |               |
| FPG ≥7.0                         | 73     | 29 (39.7)                        | 2.44 (1.38–4.32)      | 0.002       |               |
| DM+ FPG < 7.0                    | 116    | 23 (19.8)                        | 0.84 (0.48–1.48)      | 0.539       |               |
| FPG ≥7.0                         | 126    | 39 (31.0)                        | 1.51 (0.92–2.47)      | 0.104       |               |
| **LDL-C (mmol/L)**               |        |                                  |                       | 0.001       |               |
| ≥2.6                             | 331    | 103 (31.1)                       |                       |             |               |
| 1.8–2.59                         | 192    | 46 (24.0)                        | 0.63 (0.41–0.98)      | 0.041       |               |
| <1.8                             | 95     | 12 (12.6)                        | 0.27 (0.14–0.53)      | <0.001      |               |
| **BMI group**                    |        |                                  |                       | 0.595       |               |
| <24                              | 114    | 28 (24.6)                        |                       |             |               |
| 24–27.9                          | 199    | 48 (24.1)                        |                       |             |               |
| ≥28                              | 305    | 85 (27.9)                        |                       |             |               |
| **Postoperative smoking**        |        |                                  |                       |             |               |
| No                               | 398    | 87 (21.9)                        | 0.001                 | 1           |               |
| Yes                              | 220    | 74 (33.6)                        | 1.86 (1.26–2.77)      | 0.002       |               |
| **Aspirin use**                  |        |                                  |                       |             |               |
| No                               | 117    | 36 (30.8)                        | 0.197                 |             |               |
| Yes                              | 501    | 125 (25.3)                       |                       |             |               |
| **ACEI/ARB use**                 |        |                                  |                       |             |               |
| No                               | 413    | 111 (26.9)                       | 0.476                 |             |               |
| Yes                              | 205    | 50 (24.4)                        |                       |             |               |
| **Statin use**                   |        |                                  |                       | <0.001      |               |
| No                               | 205    | 74 (36.1)                        |                       | 1           |               |
| Yes                              | 413    | 87 (21.1)                        | 0.28 (0.25–0.56)      | <0.001      |               |
| **β-blocker use**                |        |                                  |                       |             |               |
| No                               | 185    | 41 (22.2)                        | 0.150                 |             |               |
| Yes                              | 433    | 120 (27.7)                       |                       |             |               |

OR, odds ratio; CI, confidence interval; CABG, coronary artery bypass grafting; HP−, patients without hypertension; HP+, patients with hypertension; BP, blood pressure; DM−, patients without diabetes; DM+, patients with diabetes; FPG, fasting plasma glucose; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

performed to identify the association between conventional RFs and LIMA graft disease. LIMA graft disease correlated with high blood glucose without diabetes (OR, 2.44; 95% CI: 1.39–4.32; P = 0.002), postoperative smoking (OR, 1.86; 95% CI: 1.26–2.78; P = 0.002) and duration of CABG ≥10 years (OR, 2.24; 95% CI: 1.33–3.78; P = 0.003). LDL-C achieved target level (OR, 0.27; 95% CI: 0.14–0.53; P < 0.001) and statin use (OR, 0.38; 95% CI, 0.25–0.56; P < 0.001). Details are given in Table 3.

**Statin Use and LDL-C Control**

Of the study, 413 patients (66.8%) were taking statins, there was no significant difference in statin use among different duration of CABG, but it appeared to be lower in women, patients aged ≥65 years, and patients with LIMA graft stenosis (p < 0.05). In total, 95 patients (15.4%) achieved target LDL-C level, and the figure was 17.4% (72/413) in treated patients. Regardless of the treated patients or the overall sample, the frequency of achieving target...
LDL-C level of patients with LIMA graft stenosis was lower than that of patients without LIMA graft stenosis (Table 4).

**DISCUSSION**

Our study indicated 26.1% of patients who had recurrence of chest pain after CABG developed stenosis in LIMA grafts. Postoperative smoking and hyperglycemia without diabetes had an increased occurrence of LIMA stenosis. Statin use and LDL-C < 1.8 mmol/L were more common in patients without LIMA stenosis.

Strong evidence supports that conventional RFs including age, sex, hypertension, diabetes, total cholesterol, obesity, and smoking, which were widely used to estimate the risk of CVD based on the risk score system (18–20). Little was known whether all of them contributed to coronary artery grafts atherosclerosis development. In the present study, we identified long duration after CABG and postoperative smoking as a potential RF; we also demonstrated a novel association between hyperglycemia without diabetes and artery graft disease. Statin use and LDL-C < 1.8 mmol/L were protective. Age, sex, hypertension, and obesity were not associated, which are quite different from other studies. For example, Shah et al. found no patients variables (age, gender diabetes, hypertension) were significantly associated with graft patency in symptomatic patients after CABG (21). Conflicting evidence was found for each conventional RFs.

Hypertension is the largest risk factor with population attributable fraction (PAFs) of 22.3% for CVD (11). But it was not associated with artery graft stenosis in the present study, the prevalence of hypertension and mean level of SBP and DBP was similar between patients with or without artery graft stenosis, which was consistent with previous study (12, 13, 21). Individuals who had no history of hypertension with BP ≥ 140/90 mmHg, it should be noted, had a high prevalence of artery graft stenosis, but the real associations might have been concealed because of the small sample size.

Diabetes is an important predictor of CVD (22), its influence on long-term patency of grafts is also important because nearly 30–40% of subjects undergoing CABG have diabetes (13–16). Conflicting evidence were reported in previous studies. Some identified diabetes as a potential predictor for graft failure (13), some showed negative association (21), and the rest showed that diabetes reduced the risk of LIMA graft stenosis (14–16). In the current study, four groups were divided according to the history of diabetes and the FPG level, hyperglycemia without diabetes had a higher prevalence of artery graft senosis than other groups, we than identified the association with OR = 2.44 (95%CI: 1.38–4.32). These individuals were suspected to be undiagnosed diabetes; they are more dangerous because most of them did not receive any hypoglycemic treatment and lifestyle intervention than previous diagnosis of diabetes. We now have a large population of undiagnosed diabetes with high percentage of 63% among patients with diabetes based on the latest national survey (23).

LDL-C lowering reduced the risk of recurrent ischemic cardiovascular events, guidelines on the management of blood cholesterol recommended a target LDL-C concentration of < 1.8 mmol/L for patients with CVD to reduce recurrent risk (24) even < 1.4 mmol/L for more benefit (25). Quin JA, et al. reported subjects who achieved a LDL-C target of < 2.6 mmol/L at 1-year did not experience improved clinical outcomes or graft patency (26). A systematic review concluded that LDL-C lowering to 1.8 mmol/L may benefit post-CABG (27). The present study indicates that LDL-C < 1.8 mmol/L had a low artery graft disease. However, the optimal target (LDL-C < 1.8 mmol/L) is seldom achieved in patients with coronary heart disease (27). Strong evidence supports the benefit of statins use with respect to the risk of recurrent cardiovascular events and improve survival have largely been attributed to reduction of LDL-C (28). Statin therapy also reduces the inflammatory cascade and promotes stability of coronary lesions vulnerable to rupture. The present study indicates that statin use could reduce the longer-term risk of artery graft stenosis, even in subjects who didn’t achieved the LDL-C target. Systematic review about statin therapy before and after CABG concluded, postoperative statins reduce the recurrence of cardiovascular events (27).

Although some cross-sectional studies did not show the association between postoperative smoking and coronary artery graft lesions (13), follow-up studies showed smoking cessation turned out to have a great effect on reducing angina pectoris or long-term mortality, the effect even greater than that of any other intervention or treatment (16, 17, 29, 30). Positive association was also found in this current study. Therefore, patients with CHD, especially those undergoing CABG should be encouraged to stop smoking. Previous studies showed 43–68% of patients undergoing CABG stopped smoking (29, 30). Continuous smoking cessation intervention is needed for patients care after CABG.

The major limitation of this study is a single center and retrospective analysis, all the information was absorbed from the hospital electronic medical records, detail information about diet, physical inactivity and dosage of medication was not collected, therefore it is likely that there is a selection and recall bias.

**TABLE 4 | Statin use and LDL-C control of the study population.**

| Characteristics         | Statin use | LDL-C < 1.8 mmol/L |
|-------------------------|------------|--------------------|
|                         | Treated patients | All patients |
| Sex                     | Male       | Female             |
| Age group (y)§           | <65        | ≥65                |
| Duration of CABG (y)§    | <5         | 5–9                | ≥10               |
| Artery graft disease§№   | No         | Yes                |

§Significant difference in statin use between the two groups (p < 0.05); §Significant difference in LDL-C control between patients with or without artery graft disease. LDL-C, low-density lipoprotein cholesterol; CABG, coronary artery bypass grafting.
related to the inquiry of medical history and the structured questionnaire. The sample size of the present study was also limited. In addition, we aimed to evaluate the effect of traditional RFs for CVD on artery graft stenosis, other RFs (1.3) that might be associated with graft stenosis were not collected and unadjusted, such as plasma fibrinogen, creatinine, and lifestyles. Glycosylated hemoglobin level was not collected because of high percentage missing value in the electronic medical record, or undiagnosed diabetes could be identified.

CONCLUSIONS
This study provides more evidence for the RFs of coronary artery grafts artery, not all conventional risk factors were positively associated with artery graft stenosis. Long duration after CABG and postoperative smoking were identified as a potential risk factor, hyperglycemia without diabetes, it should be noted, had a high prevalence of artery graft stenosis. Statin use and LDL-C <1.8 mmol/L might be protective. The results will help clinicians to take both lifestyle and pharmacological interventions to reduce artery graft lesions risk.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

REFERENCES
1. Hoye A, Lemos PA, Arampatzis CA, Sianos G, Tanabe K, Degertekin M, et al. Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery. Coron Artery Dis. (2004) 15:171–5. doi: 10.1097/00019501-200405000-00006
2. Kulik A. Secondary prevention after coronary artery bypass graft surgery: a primer. Curr Opin Cardiol. (2016) 31:635–43. doi: 10.1097/HCO.0000000000000331
3. Taggart DP, D’Amico R, Altman DG. Effect of arterial revascularization on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet. (2001) 358:870–5. doi: 10.1016/S0140-6736(01)06069-X
4. Vries MRD, Simons KH, Jukema JW, Braun J, Quax PHA. Vein graft failure: from pathophysiology to clinical outcomes. Nat Rev Cardiol. (2016) 13:451–70. doi: 10.1038/nrcardio.2016.76
5. Gaudino M, Benedetto U, Femes S, Biondi-Zoccai G, Sedrakyan A, Puskas JD, et al. for the RAAIL investigator. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. N Engl J Med. (2018) 378:2069–77. doi: 10.1056/NEJMoai1716026
6. Ruttmann E, Dietl M, Feuchner GM, Metaler B, Bonaros N, Taggart DP, et al. Long-term clinical outcome and graft patency of radial artery and saphenous vein grafts in multiple revascularization. J Thoracic Cardiovasc Surg. (2019) 158:442–50. doi: 10.1016/j.jtcvs.2018.10.135
7. Zhu Y, Chen A, Wang Z, Liu J, Cai J, Zhou Q. Ten-year real-life effectiveness of coronary artery bypass using radial artery or great saphenous vein grafts in a single centre Chinese hospital. Interact Cardiovasc Thorac Surg. (2017) 25:559–64. doi: 10.1093/icvts/ivx174
8. Tranbaugh RF, Dimitrova KR, Lucido DJ, Hoffman DM, Dincheva GR, Geller CM, et al. The second best arterial graft: a propensity analysis of the radial artery versus the free right internal thoracic artery to bypass the circumflex coronary artery. J Thorac Cardiovasc Surg. (2014) 147:133–40. doi: 10.1016/j.jtcvs.2013.08.040
9. Aldea GS, Bakaeen FG, Pal J, Freme S, Head SJ, Sabik J, et al. The society of thoracic surgeons clinical practice guidelines on arterial conduits for coronary artery bypass grafting. Ann Thorac Surg. (2016) 101:801–9. doi: 10.1016/j.athoracsur.2015.09.010
10. Sabik JF, 3rd, Lytle BW, Blackstone EH, Houghtaling PL, Cosgrove DM. Comparison of saphenous vein and internal thoracic artery graft patency by coronary system. Ann Thorac Surg. (2005) 79:544–51. doi: 10.1016/j.athoracsur.2004.07.047
11. Yusuf PS, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155722 individuals from 21 high-income, middle-income, and low-income countries (PURE) : a prospective cohort study. Lancet. (2020) 395:795–808. doi: 10.1016/S0140-6736(19)32008-2
12. Khot UN, Friedman DT, Pettersson G, Smidera NG. Li J, Ellis SC. Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts. Circulation. (2004) 109:2086–91. doi: 10.1161/01.CIR.0000127570.20508.5C
13. Yanagawa A, Alargani KD, Singh SK, Deb S, Vincent J, Ellittu R, et al. Clinical, biochemical, and genetic predictors of coronary artery bypass graft failure. J Thorac Cardiovasc Surg. (2014) 148:515–20. doi: 10.1016/j.jtcvs.2013.10.011
14. Raza S, Blackstone EH, Houghtaling PL, Rajeswaran J, Riaz H, Bakaeen FG, et al. Influence of diabetes on long-term coronary artery bypass graft patency. J Am Coll Cardiol. (2017) 70:515–24. doi: 10.1016/j.jacc.2017.05.061
15. Harskamp RE, Alexander JH, Ferguson TB, Hager R, Mack MJ, Englund B, et al. Frequency and predictors of internal mammary artery graft failure
16. Deb S, Singh SK, Moussa F, Tsibota H, Une D, Kiss A, et al. The long-term impact of diabetes on graft patency after coronary artery bypass grafting surgery: A substudy of the multicenter radial artery patency study. *Journal of Thoracic & Cardiovascular Surgery*. (2014) 148:1246–53. doi: 10.1016/j.jtcvs.2014.06.057

17. Sun HN, Hu SS, Zheng Z, Hou JF. Impact of smoking and smoking cessation on long-term outcome of patients after coronary artery bypass grafting. *Zhonghua Xin Xue Guan Bing Za Zhi*. (2011) 39:825–9. doi: 10.3760/cma.j.issn.0253-3758.2011.09.011

18. Pencina MJ, D'Agostino RB, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham heart study. *Circulation*. (2009) 119:3078–84. doi: 10.1161/CIRCULATIONAHA.108.816694

19. Wu YF, Liu XP, Li X, Li Y, Zhao L, Chen Z, et al. Estimation of 10-year risk of fatal and non fatal ischemic cardiovascular disease in Chinese adult. *Circulation*. (2006) 114:2217–23. doi: 10.1161/CIRCULATIONAHA.105.607499

20. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AC, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth Joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). *Eur Heart J*. (2016) 37:2315–81. doi: 10.1093/eurheartj/ehw106

21. Durairaj M, Shah P, Gordon J, Fuller J, Rosalion A, Sevanyanagam S, et al. Factors affecting patency of internal thoracic artery graft: clinical and angiographic study in 1434 symptomatic patients operated between 1982 and 2002. *Eur J Cardiothorac Surg*. (2004) 26:118–124. doi: 10.1016/j.ejcts.2004.02.037

22. Peters SA, Huxley RR, Woodward MD. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia*. (2014) 57:1542–51. doi: 10.1007/s00125-014-3260-6

23. Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. *JAMA*. (2017) 317:2515–23. doi: 10.1001/jama.2017.7596

24. Stone NJ, Robinson JG, Lichtenstein AH, NoedBariey Maerz C, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. A report of the American College of Cardiology/ American Heart Association task force on practice guideline. *J Am Coll Cardiol*. (2014) 63:2889–934. doi: 10.1016/j.jacc.2013.11.002

25. Mach F, Baigent C, Catapano AC, Koskina KC, Patel RS. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. (2020) 41:111–88. doi: 10.1093/eurheartj/ehz455

26. Quin JA, Hattler B, Bishawi M, Balitz J, Gupta S, Collins JF, et al. Impact of lipid-lowering medications and low-density lipoprotein levels on 1-year clinical outcomes after coronary artery bypass grafting. *J Am Coll Surg*. (2013) 217:452–60. doi: 10.1016/j.jamcollsurg.2013.04.030

27. Kulik A, Ruel M. Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety. *Expert Opin Drug Saf*. (2009) 8:559–71. doi: 10.1517/14740330903188413

28. Cheung BMY, Laufer JJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. *Br J Clin Pharmacol*. (2004) 57:640–51. doi: 10.1111/j.1365-2125.2003.02060.x

29. Domburg RTV, Reimer WSO, Hoeks SE, Kappetein AP, Boqers AJC. Three life-years gained from smoking cessation after coronary artery bypass surgery: A 30-year follow-up study. *Am Heart J*. (2008) 156:473–6. doi: 10.1016/j.ahj.2008.04.007

30. Papahaniasiou A, Milionis H, Toupoumidis I, Kalantzis K, Katsouras C, Pappas K, et al. Smoking cessation is associated with reduced long-term mortality and the need for repeat interventions after coronary artery bypass grafting. *Eur J Cardiovasc Prev Rehabil*. (2007) 14:448–50. doi: 10.1097/HJR.0b013e3280403e68

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zuo, Nan, Yang, Wang and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.